- 全部删除
- 您的购物车当前为空
Sonepcizumab (LT 1009) 是一种完全人源化的抗 S1P 单克隆抗体。Sonepcizumab 具有抗癌活性,可用于研究转移性肾细胞癌 (mRCC) ,可预防青光眼滤过手术后的眼部瘢痕形成。
为众多的药物研发团队赋能,
让新药发现更简单!
Sonepcizumab (LT 1009) 是一种完全人源化的抗 S1P 单克隆抗体。Sonepcizumab 具有抗癌活性,可用于研究转移性肾细胞癌 (mRCC) ,可预防青光眼滤过手术后的眼部瘢痕形成。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 2,880 | In stock | |
2 mg | ¥ 4,180 | In stock | |
5 mg | ¥ 6,570 | In stock | |
10 mg | ¥ 8,860 | In stock | |
25 mg | ¥ 12,900 | In stock | |
50 mg | ¥ 17,700 | In stock | |
100 mg | ¥ 23,900 | In stock |
产品描述 | Sonepcizumab (LT 1009) is a fully humanized monoclonal antibody against S1P. Sonepcizumab has anti-cancer activity and can be used to study metastatic renal cell carcinoma (mRCC) to prevent eye scarring after glaucoma filtration surgery. |
别名 | LT 1009 |
分子量 | 146.43 kDa |
CAS No. | 1031360-18-5 |
存储 | store at low temperature | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容